Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer

NCT04633252 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT04633252
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04633252 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 23, 2021
Completion date
December 31, 2026
Enrollment
86 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of prostate, prostate neoplasms